View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

   reports
ABGSC Food & Beverage Research ... (+2)
  • ABGSC Food & Beverage Research
  • Sten Gustafsson
PROB PROBI AB

Slow start, but turnaround continues

Drop in sales due to tough comps. Gross margin negatively impacted by mix effects. EBITDA revised down 8-9% for '24e-'26e.

04/23/24 April 23, 2024 1 EN
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Erik Cassel
  • Gonzalo Castanon
PROB PROBI AB

Probi - Weak Q3, but hope for 2023

Q3 result in line with pre-announced numbers US weaker in Q3; expect resumed group growth in 2023 Share trading at NTM EV/EBITA of 14x

10/24/22 October 24, 2022 1 EN
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Erik Cassel
  • Jakob Lembke
PROB PROBI AB

Probi - Cautious outlook in Americas

Sales stabilising and EBITDA 7% above ABGSCe… … but macroeconomic environment could hurt demand ‘23e EBITDA down 2%, NTM EV/EBITA 20x

07/19/22 July 19, 2022 1 EN
Free Trial
PROB PROBI AB

Probi AB: 1 director

A director at Probi AB bought 1,355 shares at 302.075SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

05/03/22 May 3, 2022 1 EN
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Erik Cassel
  • Jakob Lembke
PROB PROBI AB

Probi - Weaker performance to stabilise in Q2

-16% organic growth on another weak Americas quarter Turning point in Q2, growth in H2 EBIT estimates down 24%

04/27/22 April 27, 2022 1 EN
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Erik Cassel
  • Jakob Lembke
PROB PROBI AB

Probi - Impressive gross margin in Q4

Gross margin improvement offsets weaker sales 2022 will be a better year than 2021 ‘22e EBIT up 4% on FX, higher gross margin

02/04/22 February 4, 2022 1 EN
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Erik Cassel
  • Jakob Lembke
PROB PROBI AB

Probi - North American weakness only short-term

North America below, but EBITDA margin held up Lower expectations for Q4 but outlook remains positive ’21-‘22e EBITDA down 5%; share at 31x ‘22e EV/EBIT

10/22/21 October 22, 2021 16 EN
Jakob Lembke ... (+3)
  • Jakob Lembke
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - A bump in the road

Lower than expected North America revenues Multiple new partnerships announced during the quarter EBIT estimates down 19%-11%; 37x ’22e EV/EBIT

07/19/21 July 19, 2021 17 EN
PREMIUM
GETI B Getinge AB Clas...
PHO PHOTOCURE ASA ... (+18)

Sector Fast Comment - Life Science Summit 2021

50 Nordic life science companies – replay links attached COVID-19 recovery on the agenda AstraZeneca’s EVP Int. on the Chinese market

GETI B GETINGE AB CLASS B
PHO PHOTOCURE ASA
ELOS B ELOS MEDTECH AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
HRTIS HERANTIS PHARMA OYJ
PROB PROBI AB
TRVX TARGOVAX AS
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
PCIB PCI BIOTECH HOLDING ASA
ULTI ULTIMOVACS
IVACC INTERVACC AB
QLINEA Q LINEA AB
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
CLNK B CELLINK AB
NANEXA NANEXA AB
05/31/21 May 31, 2021 2 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PREMIUM
PROB PROBI AB

Probi - EMEA staging a comeback

Q1’21: 20% organic growth vs. ABGSCe 16% Growing above financial target, EBITDA slightly below Continued positive outlook for 2021 and beyond

04/23/21 April 23, 2021 5 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - Committed to growth

20% organic growth vs. ABGSCe 12% Investing in growth; expecting to reach financial goals 34x-29x EV/EBIT ‘21e-‘22e for 11% EBIT CAGR ’20-‘23e

02/10/21 February 10, 2021 17 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - Americas continues to deliver strong growth

Q4’20: 20% organic growth Product mix and higher costs weighs on profitability Positive wording for 2021

02/09/21 February 9, 2021 5 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - Americas set to steal the show again

Q4 report on Tuesday, 9 February, at 08:00 CET Negative EBIT revisions primarily driven by FX 34x EBIT ‘21e on ~8.5% EBIT CAGR ‘20e-‘23e

01/11/21 January 11, 2021 12 EN
MarketLine Department
  • MarketLine Department
EUR 324.94
BIOG B BioGaia AB Seri...
PROB PROBI AB ... (+3)

Cloetta AB - Mergers & Acquisitions (M&A), Partnerships & Alliances An...

Summary Marketline's Cloetta AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Cloetta AB since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic g...

BIOG B BIOGAIA AB SERIES B
PROB PROBI AB
AAK AAK AB
10/29/20 October 29, 2020 93 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - Americas leads the way

Strong growth in Americas outshines softer EMEA/APAC Acquires ~10% stake (USD 6m) in Vital Nutrients We raise EBIT by 9%-6% ’20e-’22e

10/21/20 October 21, 2020 16 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - A record quarter boosted by the US

Q3’20: 43% organic growth helped by positive one-off EBITDA +24% vs. ABGSCe; margin slightly below We expect +10-12% cons estimate revisions for ‘20 EBIT

10/21/20 October 21, 2020 6 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - Healthy new ambitions

Flat sales y-o-y (-2% organic); +2% vs. ABGSCe Updated financial goals seem achievable 28-21x EV/EBIT ’20e-’22e for 8% EBIT CAGR ’19-’22e

07/19/20 July 19, 2020 14 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - Solid underlying demand amidst COVID-19

11% organic growth with 2.7% EBIT decline Confident outlook for ‘20 with risk of quarterly turbulence 4-3.5x EV/Sales ‘20e-’21e, 28-19x EV/EBIT ‘20e-’21e

04/27/20 April 27, 2020 16 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - Limited COVID-19 impact expected for 2020

Organic sales +11% y-o-y vs. ABGSCe +8.8% 39% (42% Q1’19) GM hit by unfavourable product mix Positive outlook for 2020 with solid near-term order book

04/24/20 April 24, 2020 6 EN
Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg
PROB PROBI AB

Probi - Q4: Leaving a challenging 2019 behind

Beating all expectations for Q4’19 New growth strategies amidst lowered market growth 20.5x EV/EBIT ’20e on ~9% EBIT CAGR ’19-’23e

02/11/20 February 11, 2020 14 EN
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest
Save

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search
Save

ResearchPool Subscriptions

Get the most out of your insights

Get in touch